Published in Blood Weekly, December 30th, 2004
The panel advised conducting additional studies with clofarabine in acute myeloid leukemia (AML) before recommending an approval in this harder-to-treat leukemia, for which the company also submitted data.
Under the Prescription Drug User Fee Act, the FDA has until December 30, 2004 to complete the review of the clofarabine new drug application (NDA). The proposed branded name for clofarabine in North America is...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.